John Fanikos Shares Greg Piazza’s Presentation On The Results of The HI-Pro Trial
John Fanikos, Director of Strategic Initiatives at North American Thrombosis Forum, shared on LinkedIn:
”The best part of my pharmacist career was spending time with the Thrombosis Research Group.
Dr. Greg Piazza presented the results of the HI-Pro Trial at the European Society Meeting over the Labor Day weekend in Madrid, Spain.
There are often reasons (surgery, infection, injury) patients developed blood clots (deep vein thrombosis and pulmonary embolism) in their legs and lungs.
These events were called “provoked” and treated with medicines (anticoagulants) for 3-6 months.
Dr. Piazza’s research suggests treating longer, and with a lower dose, may prevent repeat events and be better for patients.
Kudos to the research group. Kudos to the Investigational Drug Service Pharmacy (IDS) that delivered the drugs by foot, by FedEx, and by UPS in the peri-pandemic period to keep patients on their medications.
I was honored to be included.”
Stay updated on the latest news in the field of thrombosis with Hemostasis Today.
-
Feb 18, 2026, 16:47Sophia Delicou: Importance of Assessing Hemoglobin Functional Capacity Rather Than Total Levels
-
Feb 18, 2026, 16:32Cheng-Hock Toh: 5 Steps to Transform Transfusion Practice
-
Feb 18, 2026, 16:26Tareq Abadl: CMV and Transfusion – Leukoreduction vs CMV-Seronegative
-
Feb 18, 2026, 16:24Soroush Sohrabi: The Hidden Biology of Sclerotherapy and Mechanisms Beyond Endothelial Injury
-
Feb 18, 2026, 16:23Hamad Abbasi: Why are Coronary Stents so Expensive?
-
Feb 18, 2026, 16:08Carlos Doti: AstraZeneca’s Expanding Impact in Blood Cancer Care
-
Feb 18, 2026, 16:05Shiny K. Kajal: Routine vs Massive Transfusion Protocol
-
Feb 18, 2026, 16:03Maria Farid: Successful Consultative Hematology and Transfusion Medicine Workshop at PKLI
-
Feb 18, 2026, 15:59Ella Lawson: Could Erythritol Harm the Brain’s Blood Vessels?